Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 2, 1999, Pages 127-132

  Reiter, Lawrence A ^a   Rizzi, James P ^a   Pandit, Jayvardan ^a   Lasut, Michael J ^a   McGahee, Shunda M ^a   Parikh, Vinod D ^a   Blake, James F ^a   Danley, Dennis E ^a   Laird, Ellen R ^a   Lopez Anaya, Arturo ^a   Lopresti Morrow, Lori L ^a   Mansour, Mahmoud N ^a   Martinelli, Gary J ^a   Mitchell, Peter G ^a   Owens, Brian S ^a   Pauly, Thomas A ^a   Reeves, Lisa M ^a   Schulte, Gayle K ^a   Yocum, Sue A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; PHOSPHINIC ACID DERIVATIVE;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS;

BINDING SITES; COLLAGENASES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; INHIBITORY CONCENTRATION 50; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MODELS, MOLECULAR; PHOSPHINIC ACIDS;

EID: 0033579979     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00729-X     Document Type: Article

References (25)

1. Denis, L. J.; Verweij, J. Invest. New Drugs 1997, 15, 175. Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Crit. Rev. Oral Biol. Med. 1993, 4, 197. Woessner, J. F., Jr. FASEB J. 1991, 5, 2145.
2. Denis, L. J.; Verweij, J. Invest. New Drugs 1997, 15, 175. Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Crit. Rev. Oral Biol. Med. 1993, 4, 197. Woessner, J. F., Jr. FASEB J. 1991, 5, 2145.
3. Denis, L. J.; Verweij, J. Invest. New Drugs 1997, 15, 175. Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Crit. Rev. Oral Biol. Med. 1993, 4, 197. Woessner, J. F., Jr. FASEB J. 1991, 5, 2145.
4. For current reviews and leading references to previous reviews and the extensive related literature see: Beckett, R. P.; Whittaker, M. Exp. Opin. Ther. Patent 1998, 8, 259; Bottomley, K. M.; Johnson, W. H.; Walter, D. S. J. Enzyme Inhib. 1998, 13, 79. Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Curr. Pharm. Des. 1996, 2, 624.
5. For current reviews and leading references to previous reviews and the extensive related literature see: Beckett, R. P.; Whittaker, M. Exp. Opin. Ther. Patent 1998, 8, 259; Bottomley, K. M.; Johnson, W. H.; Walter, D. S. J. Enzyme Inhib. 1998, 13, 79. Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Curr. Pharm. Des. 1996, 2, 624.
6. For current reviews and leading references to previous reviews and the extensive related literature see: Beckett, R. P.; Whittaker, M. Exp. Opin. Ther. Patent 1998, 8, 259; Bottomley, K. M.; Johnson, W. H.; Walter, D. S. J. Enzyme Inhib. 1998, 13, 79. Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Curr. Pharm. Des. 1996, 2, 624.
7. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T.; Schnierer, S.; Tschesche, H. EMBO J. 1994, 13, 1283.
8. 1 "spacers" showed only very weak inhibition of MMP-1 activity at 30000 nM.
9. Bis(trimethylsilyl)phosphonite was prepared as described in: (a) Boyd, E. A.; Regan, A. C.; James, K. Tetrahedron Lett. 1992, 33, 813.
10. (b) ibid. 1994, 35, 4223.
11. (c) The Michael reaction was performed as described in: Boyd, E. A.; Corless, M.; James, K.; Regan, A. C. Tetrahedron Lett. 1990, 31, 2933.
12. Stetter, H; Kuhlmann, H. Synthesis 1979, 29.
13. Thottathil, J. K.; Przybyla, C. A.; Moniot, J. L. Tetrahedron Lett. 1984, 25, 4737.
14. Hashimoto, N.; Aoyama, T.; Shioiri, T. Chem. Pharm. Bull. 1981, 29, 1475.
15. Reiter, L. A.; Jones, B. P. J. Org. Chem. 1997, 62, 2808.
16. Caldwell, C. G.; Sahoo, S. P.; Polo, S. A.; Eversole, R. R.; Lanza, T. J.; Mills, S. G.; Niedzwiecki, L. M.; Izquierdo-Martin, M.; Chang, B. C.; Harrison, R. K.; Kuo, D. W.; Lin, T.-Y.; Stein, R. L.; Durette, P. L.; Hagmann, W. K. Bioorg. Med. Chem. Lett. 1996 6, 323.
17. 50's were determined by the method of Bickett et al. (ref 18) using recombinant MMP-1 (expressed in baculovirus).
18. 1′.
19. Fora discussion of the binding of inhibitors to various MMP's see: Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359.
20. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Drug Disc. Today 1996, 1, 16.
21. 50's were determined by the method of Bickett et al. (ref 18) using recombinant MMP-13 (expressed in baculovirus).
22. 1′ pocket of MMP-1. These angles are greatly influenced by the geometry that the hydroxamate and phosphinate ligands assume upon binding to the active site zinc.
23. a of 10 was measured to be 2.8.
24. Bickett, D. M.; Green, M. D.; Berman, J.; Dezube, M.; Howe, A. S.; Brown, P. J.; Rothand, J. T.; McGeehan, G. M. Anal. Biochem. 1993, 212, 58.
25. Gowravaram, M. R.; Tomczuk, B. E.; Johnson, J. S.; Delecki, D.; Cook, E. R.; Ghose, A. K.; Mathiowetz, A. M.; Spurlino, J. C.; Rubin, B.; Smith, D. L.; Pulvino, T.; Wahl, R. C. J. Med. Chem. 1995, 38, 2570.